



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Lunsumio

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
X/0015	Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration Annex I_2.(c) Change or addition of a new strength/potency	18/09/2025	17/11/2025	SmPC, Annex II, Labelling and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



R/0014	Renewal of the marketing authorisation.	27/02/2025	14/04/2025	Annex II	The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Lunsumio, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.
PSUSA/10999/202406	Periodic Safety Update EU Single assessment - mosunetuzumab	16/01/2025	n/a		PRAC Recommendation - maintenance
IB/0013	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	11/10/2024	n/a		
PSUSA/10999/202312	Periodic Safety Update EU Single assessment - mosunetuzumab	25/07/2024	19/09/2024	SmPC, Annex II and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10999/202312.
R/0008	Renewal of the marketing authorisation.	22/02/2024	19/04/2024		
IB/0011/G	This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or	17/04/2024	19/09/2024	SmPC	

	starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation				
IB/0009/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	17/04/2024	19/09/2024	Annex II	
PSUSA/10999/202306	Periodic Safety Update EU Single assessment - mosunetuzumab	25/01/2024	21/03/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10999/202306.
IB/0007/G	This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological	19/10/2023	21/03/2024	SmPC	

	medicinal product in accordance with an approved stability protocol A.6 - Administrative change - Change in ATC Code/ATC Vet Code				
IB/0005	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	10/10/2023	n/a		
IA/0006	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	25/09/2023	n/a		
PSUSA/10999 /202212	Periodic Safety Update EU Single assessment - mosunetuzumab	06/07/2023	n/a		PRAC Recommendation - maintenance
II/0002/G	This was an application for a group of variations. B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	12/05/2023	n/a		
R/0001	Renewal of the marketing authorisation.	23/02/2023	19/04/2023	Annex II and PL	The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Lunsumio, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.

					Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other minor editorial changes have been implemented.
--	--	--	--	--	--